Jacques-François Martin to chair Anergis
This article was originally published in Scrip
Executive Summary
Anergis, a clinical-stage biopharmaceutical company developing allergy vaccines, has appointed Jacques-François Martin chair of the board. Mr Martin is currently chair and CEO of Mymetics, and was previously CEO of Chiron Vaccines, now Novartis. He has also served in leadership positions for non-profit organisations and was the first president and CEO of The Vaccine Fund (Bill and Melinda Gates Foundation) from 2000-2005.